The PRI Executive Committee, Board of Directors, and especially the staff are excited to announce our latest achievement in our EU Regulatory Strategy:
The Pharmabiotic Research Institute (PRI) has been identified and registered as an official stakeholder with the European Commission.
This is an important milestone as we continue to strive to clarify the specific regulatory and technical requirements for microbiome-based medicinal products developed for the European market.
